Real-World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug-Resistant HIV-1 in Southeastern France. (PubMed, J Med Virol) - Sep 12, 2026 - "In one of these 3 persistently viremic PWH, a dual-injectable rescue regimen combining lenacapavir and cabotegravir achieved viral suppression at 33 months with maintenance through the end of follow-up, bringing the success rate to 9 out of 11 (82%) among PWH who were viremic at baseline. A dual-injectable rescue regimen may represent a last-resort option in selected complex cases. Similar real-world studies should be expanded, and adherence support should be strengthened."
Journal • Real-world evidence • Retrospective data • Human Immunodeficiency Virus • Infectious Disease • CD4
|
|
Amelie Menard; Caroline Solas; Céline Boschi; Christelle Tomei; Hugo Bes-Barlandier; Isabelle Ravaux; Matthieu Million; Nadège Néant; Philippe Colson; Saadia Mokhtari; Syrine Boujamline; Yacine Belkhir
|